Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Longitudinal associations between chronic health condition burden and financial hardship among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor study (CCSS).

Tara Suntum, Yan Chen, Nickhill Bhakta et al. Jun 01, 2025 pp. 10057-10057 10.1200/jco.2025.43.16_suppl.10057

10057 Background: Childhood cancer survivors experience a large burden of chronic health conditions (CHCs) with the progression of these conditions facili...

Efficacy and safety of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: A systematic review and meta-analysis of randomised controlled trials.

Kamran Habib, Shariq Ahmad Wani, Bara M. Hammadeh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13010

e13010 Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) showing significant promise in treatment of metastatic HER2+ an...

The difference of clinical and molecular characteristics between HR-positive/HER2-positive and HR-negative/HER2-positive early breast cancer: A secondary analysis of 11 clinical trials.

Hongmei Zheng, Yalong Yang, Jianhua Liu et al. Jun 01, 2025 pp. 533-533 10.1200/jco.2025.43.16_suppl.533

533 Background: HER2+ early breast cancer (EBC) are treated as an identical cluster of patients in clinical practice. However, the various status of hormo...

Immunotherapy toxicity in the curative setting.

Amal AlJuhani, Neha Pathak, Brooke E. Wilson et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14579

e14579 Background: Immune checkpoint inhibitors (ICI) improve survival in the curative setting. Understanding the impact, severity, and long-term toxicity...

Trends and disparities in alcohol use and liver cell carcinoma–related mortality in the US: A 24-year retrospective study.

Azka Aisha, Abdul Qadeer, Sardar Muhammad Imran Khan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16237

e16237 Background: Alcohol use (AU) and Liver cell carcinoma (LCC) are significant contributors to adult mortality worldwide. Examining trends and dispari...

Target therapy adoption for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): A five-year real-world analysis.

Pierantonio Russo, Ramaa Nathan, Daniel Pfeffer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23283

e23283 Background: Molecular testing (MT) is a cornerstone of precision oncology in hematological malignancies, yet its integration into routine practice...

TACE with or without lenvatinib as adjuvant therapy for HCC with microvascular invasion (MVI) or portal vein thrombus (Cheng’s I/II): A single-center, prospective, non-randomized cohort study.

Chengpei Zhu, Feng Wu, Zibo Xu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16214

e16214 Background: Hepatocellular carcinoma (HCC) with microvascular invasion (MVI) or portal vein tumor thrombus (PVTT) is associated with a high risk of...

Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria.

Wendy Kohlmann, Karen Curtin, Michael J. Madsen et al. Jun 01, 2025 pp. 11570-11570 10.1200/jco.2025.43.16_suppl.11570

11570 Background: Data regarding the heritability of rare tumors is limited and may prevent incorporation into genetic testing criteria. This study utiliz...

Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer.

Zhenyu Lin, Xueli Bai, Xinjun Liang et al. Jun 01, 2025 pp. 104-104 10.1200/jco.2025.43.16_suppl.104

104 Background: The prognosis of patients (pts) with microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) who failed standa...

The cancer fusionome and overexpressed druggable oncogenic signals in <i>K-RAS</i> wild-type pancreatic cancer.

Michal Krawczyk, Roisin Puentes, Nathan Montgomery et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15180

e15180 Background: Pancreatic cancer has apoor prognosis and limited therapeutic options. While K-RAS mutations are prevalent in t...

Gut microbiome changes in pediatric AML and association with event free survival.

Oren Gordon, Jennifer Fouquier, Bryan Nycz et al. Jun 01, 2025 pp. 10026-10026 10.1200/jco.2025.43.16_suppl.10026

10026 Background: Pediatric acute myeloid leukemia (AML) is characterized by months of hospitalization with a high risk for infections and a higher rate o...

The non-canonical role of homologous recombination deficiency in the development of immune-cold tumor microenvironment.

Aravindan Vasudevan, Aarthi Ramesh, Ankit Jain et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15032

e15032 Background: Homologous recombination deficiency (HRD) is an event triggered by impairment of the homologous recombination repair (HRR) pathway whic...

Exploring the prevalence of germline mutations in young-onset biliary tract cancer (BTC).

Osama M. MoSalem, Guido Chiriboga, Aya Elalfy et al. Jun 01, 2025 pp. 10587-10587 10.1200/jco.2025.43.16_suppl.10587

10587 Background: The American Society of Clinical Oncology (ASCO) and NCCN recommend germline testing for patients (pts) with biliary tract cancers (BTC)...

Characteristics and concomitant congenital abnormalities among newborns with cancer: A population level analysis.

Sergio Hernandez-Llamas, Laura Reyes-Uribe, Jorge Luis Rodriguez Vazquez et al. Jun 01, 2025 pp. 10071-10071 10.1200/jco.2025.43.16_suppl.10071

10071 Background: Congenital cancers are rare, occurring in 223 per million infants annually. Neuroblastoma, leukemia, and CNS tumors are most common. Up...

Prostate adenocarcinoma to neuroendocrine tumor: A therapy-driven response?

Noah Ritschard, Jentry Lange Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17024

e17024 Background: Androgen deprivation therapy (ADT) remains a cornerstone of treatment for prostate cancer. Some androgen-dependent prostate cancers evo...

HAIC plus TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma: The REACH-01 trial.

Kangshuai Li, Tiezhong Zhang, Qiang Gao et al. Jun 01, 2025 pp. 4087-4087 10.1200/jco.2025.43.16_suppl.4087

4087 Background: REACH-01 (NCT06239532) is a single-arm, open label, prospective trial, aiming to evaluate the safety and preliminary effectiveness of hep...

Using tumor growth modeling and informed neural networks as early predictive clinical endpoints.

Mehdi Felfli, Sebastien Jacques, Alexandre Thinnes et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13590

e13590 Background: Immunotherapy has significantly improved cancer treatment outcomes but presents unique challenges in assessing response due to complex...

Predictive value of circulating tumor DNA detection for long-term survival in patients with advanced lung cancer undergoing chemoimmunotherapy.

Hui Li, Sizhe Yu, Yanjun Xu et al. Jun 01, 2025 pp. 8559-8559 10.1200/jco.2025.43.16_suppl.8559

8559 Background: Chemoimmunotherapy (ChemoIO) has emerged as the first-line standard treatment option for advanced non-small cell lung cancer (NSCLC) with...

Association of sodium-glucose co-transporter-2 inhibitors with cardiac outcomes and mortality in cancer patients: A systematic review and meta-analysis.

Sufyan Shahid, Humza Saeed, Minahil Iqbal et al. Jun 01, 2025 pp. 12022-12022 10.1200/jco.2025.43.16_suppl.12022

12022 Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) have proven effective in improving cardiac outcomes, including heart failure (HF) h...

Bridging the gap: Palliative care outcomes in academic versus community centers for advanced non-small cell lung cancer patients.

Moazzam Shahzad, Nouman Aziz, Sarmad Zaman Warraich et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23081

e23081 Background: The impact of care at academic versus community centers for palliative management of non-small cell lung cancer (NSCLC) remains underex...

Comparing the impact of nivolumab &amp; ipilimumab combination therapy vs. dabrafenib &amp; trametinib on outcomes in malignant melanoma patients: A global propensity-matched retrospective cohort study.

Abdul Wahab, Abdul Wali Khan, Muhammad Ishaq et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21604

e21604 Background: Malignant melanoma is a highly aggressive skin cancer with a high mortality rate. Thenivolumab-ipilimumab combination therapy and dabra...

Single-slide histology-based deep learning model for mismatch repair deficiency prediction in colorectal cancer.

Masoud Tafavvoghi, Elio Adib, Elias Bou Farhat et al. Jun 01, 2025 pp. 3567-3567 10.1200/jco.2025.43.16_suppl.3567

3567 Background: Mismatch repair deficiency (dMMR) is a critical predictive biomarker for determining eligibility and response to immunotherapy in colorec...

Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence.

Thomas O'Keefe, Christina Yau, Sophie Lin et al. Jun 01, 2025 pp. 572-572 10.1200/jco.2025.43.16_suppl.572

572 Background: The treatment of DCIS is still primarily informed by trials that are now decades old. We have learned since then that only invasive subseq...

A retrospective study of pyrotinib for advanced salivary duct carcinoma (SDC) with positive HER2 expression.

Qing Ji, Jun Cao, Meiyu Fang Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18148

e18148 Background: Salivary duct carcinoma (SDC) is a rare subtype of thyroid cancer with a poor prognosis. The efficacy and safety of human epidermal gro...

Trends in cancer incidence in Singapore over the last two decades.

Hui Miao, Evelyn Yi Ting Wong, Kennedy Ng et al. Jun 01, 2025 pp. 10554-10554 10.1200/jco.2025.43.16_suppl.10554

10554 Background: Singapore has witnessed a significant rise in cancer incidence over recent decades. The most rapid increase in age-specific incidence of...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page